Skip to search formSkip to main contentSkip to account menu

trovafloxacin

Known as: 7-(6-amino-3-azabicyclo[3.1.0]hex-3-yl)- 1-(2,4-difluorophenyl)- 6-fluoro-4-oxo-[1,8] naphthyridine-3-carboxylic acid, trovafloxacin [Chemical/Ingredient] 
National Institutes of Health

Related topics

Related topics

23 relations

Broader (4)

Anti-Infective AgentsFluoroquinolonesNaphthyridinesTopoisomerase II Inhibitors
Bacteroides InfectionsBronchitisChlamydia InfectionsDecreased Protein Synthesis [PE]

Narrower (1)

CP 99219

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2003
Review
2003
Five-year analysis of Haemophilus influenzae isolates with reduced susceptibility to fluoroquinolones: prevalence results from the SENTRY antimicrobial surveillance program.
Highly Cited
1999
Highly Cited
1999
Prediction of the antimicrobial effects of trovafloxacin and ciprofloxacin on staphylococci using an in-vitro dynamic model.
To compare the pharmacodynamics of trovafloxacin and ciprofloxacin, three clinical isolates of Staphylococcus aureus with… 
Highly Cited
1998
Highly Cited
1998
In Vitro Activity of BAY 12-8039, a New Fluoroquinolone, against Mycoplasmas
ABSTRACT The in vitro activity of the fluoroquinolone BAY 12-8039 against 66 strains of different mycoplasma species and 30… 
Review
1997
Review
1997
Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?
The pharmacology, spectrum of activity, pharmacokinetics, clinical efficacy, and adverse effects of levofloxacin, recently… 
Highly Cited
1997
Highly Cited
1997
In-vitro activity of trovafloxacin, a new fluoroquinolone, against recent clinical isolates.
Trovafloxacin (CP-99,219) was very active against Gram-negative species examined including Haemophilus influenzae, Moraxella… 
Highly Cited
1997
Highly Cited
1997
Concentrations of trovafloxacin in bronchial mucosa, epithelial lining fluid, alveolar macrophages and serum after administration of single or multiple oral doses to patients undergoing fibre-optic…
Concentrations of trovafloxacin were measured in serum, alveolar macrophages, epithelial lining fluid and bronchial mucosa… 
Highly Cited
1997
Highly Cited
1997
Comparative activity of trovafloxacin, alone and in combination with other agents, against gram-negative nonfermentative rods
In the first part of this study, agar dilution MICs were used to test the activities of trovafloxacin, ciprofloxacin, ofloxacin… 
Highly Cited
1996
Highly Cited
1996
Activity of the new fluoroquinolone trovafloxacin (CP-99,219) against DNA gyrase and topoisomerase IV mutants of Streptococcus pneumoniae selected in vitro
The MICs of trovafloxacin, ciprofloxacin, ofloxacin, and sparfloxacin at which 90% of isolates are inhibited for 55 isolates of… 
Highly Cited
1995
Highly Cited
1995
Pharmacokinetics and safety of trovafloxacin (CP-99, 219), a new quinolone antibiotic, following adminstration of single oral doses to healthy male volunteers
Trovafloxacin (CP-99,219) is a new fluoroquinolone antibacterial agent with a broad spectrum of activity against Gram-positive… 
Review
1988
Review
1988
Safety Overview: Toxicity, Adverse Effects, and Drug Interactions
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)